3D QUANTITATIVE STRUCTURE–ACTIVITY RELATIONSHIP DESIGNING AND MOLECULAR DOCKING STUDY OF NOVEL THIADIAZOLE DERIVATIVES AS A POTENTIAL ANTI-CANCER AGENT

3D QUANTITATIVE STRUCTURE–ACTIVITY RELATIONSHIP DESIGNING AND MOLECULAR DOCKING STUDY OF NOVEL THIADIAZOLE DERIVATIVES AS A POTENTIAL ANTI-CANCER AGENT INDHUMATHY P GANDHIMATHI R

Objective: Melanoma, which arises from uncontrolled melanocyte growth, can be treated with surgery in the early stages but poses challenges in advanced cases. This study used 3D quantitative structure–activity relationship (3D QSAR) and docking methods to evaluate 51 molecules and to identify compounds with significant binding affinity to BRAF protein. The objective of this study is to design and evaluate novel thiadiazole derivatives as potential anti-cancer agents using a combination of 3D-QSAR modeling and molecular docking studies. Methods: The study employs a 3D QSAR approach to analyze the inhibitory activity of 51 selected molecules against BRAF, a key target in cancer research. The methodology is structured as follows. A total of 51 molecules were retrieved from the literature based on their documented inhibitory activity against BRAF. These molecules were curated and preprocessed to ensure consistency and accuracy for further computational analysis. Molecular descriptors, which quantitatively represent molecular properties, were generated to facilitate the QSAR modeling process. These descriptors were essential for establishing a correlation between molecular features and biological activity. The Schrödinger software suite was employed to conduct the 3D QSAR analysis. The model was built using ligand-based and structure-based approaches, incorporating spatial and electronic properties to predict activity. To further validate the binding potential of these molecules, PyRx software was utilized for molecular docking studies. Docking simulations helped assess the binding interactions between the molecules and the BRAF protein, offering insights into potential drug-receptor affinity. This methodology allows for the identification of key structural features contributing to BRAF inhibition, providing a foundation for the design of more potent inhibitors in future research. Results: The Gaussian-based QSAR was produced by correlating with the five fields of steric, electrostatic, hydrophobic, hydrogen bond donor (HBD), and hydrogen bond acceptor (HBA) with the aid of PLS with five variables. With a standard error estimate of 0.2 and an F ratio of 80.3, r2cv values of 0.47 and r2 0.93 were obtained. The steric, HBA, hydrophobic, HBD, electrostatic, and field contributions were, in order, 0.29, 0.08, 0.24, 0.18, and 0.188. Based on the structure of this best descriptor, novel 25 thiadiazole derivatives were designed. For these 25 novel molecules, a docking study was performed using PyRx software. Conclusion: The results of this study indicate that the thiadiazole ring’s (HBD) and (HBA) substituents are crucial to the drug’s BRAF antagonistic action. Good r2 = 0.93 was displayed by the Gaussian models that were developed based on the five field intensities. The docking studies revealed that the derivative IA25 (−9.7 k/cal) showed a similar binding affinity of standard molecule Dabrafenib toward the targeted protein and these molecules showed 2 conventional hydrogen bonds with Asn221 and Phe209 amino acid residues. The remaining compounds showed the docking score range from 8 k/cal to 9.6 k/cal. Based on the docking score 10 molecules are selected for further studies.
05 07 2025 111 117 http://creativecommons.org/licenses/by/4.0 10.22159/ajpcr.2025v18i5.54287 https://www.innovareacademics.in/journals/index.php/ajpcr/article/view/54287 https://www.innovareacademics.in/journals/index.php/ajpcr/article/download/54287/31986 https://www.innovareacademics.in/journals/index.php/ajpcr/article/download/54287/31986 10.3390/molecules25184309 Janowska S, Paneth A, Wujec M. Cytotoxic properties of 1,3,4-thiadiazole derivatives-a review. Molecules. 2020;25(18):4309. doi: 10.3390/molecules25184309, PMID 32962192. 10.1002/ijc.31937 Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-53. doi: 10.1002/ijc.31937, PMID 30350310. 10.1007/978-3-031-28780-0_60 Ghufran MS, Soni P, Duddukuri GR. The global concern for cancer emergence and its prevention: A systematic unveiling of the present scenario. Bioprospecting of Tropical Medicinal Plants. Switzerland: Cham Springer Nature; 2023. p. 1429-55. 10.4103/jcrt.JCRT_785_19 Labani S, Asthana S, Rathore K, Sardana K. Incidence of melanoma and nonmelanoma skin cancers in Indian and the global regions. J Cancer Res Ther. 2021;17(4):906-11. doi: 10.4103/jcrt.JCRT_785_19, PMID 34528540. 10.1016/j.medidd.2022.100150 Kumar D, Kumar H, Kumar V, Deep A, Sharma A, Marwaha MG, et al. Mechanism-based approaches of 1,3,4 thiadiazole scaffolds as potent enzyme inhibitors for cytotoxicity and antiviral activity. Drug Discov. 2023;17:100150. doi: 10.1016/j.medidd.2022.100150. 10.3390/cancers12071823 Proietti I, Skroza N, Michelini S, Mambrin A, Balduzzi V, Bernardini N, et al. BRAF inhibitors: molecular targeting and immunomodulatory actions. Cancers (Basel). 2020;12(7):1823. doi: 10.3390/ cancers12071823, PMID 32645969. 10.18632/oncotarget.27304 Croce L, Coperchini F, Magri F, Chiovato L, Rotondi M. The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget. 2019;10(61):6623- 40. doi: 10.18632/oncotarget.27304, PMID 31762942. 10.1038/s41392-023-01705-z Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct Target Ther. 2023;8(1):455. doi: 10.1038/s41392-023-01705-z. PMID 38105263. 10.3390/cancers14174264 Talloa D, Triarico S, Agresti P, Mastrangelo S, Attinà G, Romano A, et al. BRAF and MEK targeted therapies in pediatric central nervous system tumors. Cancers (Basel). 2022 Aug 31;14(17):4264. doi: 10.3390/cancers14174264, PMID 36077798. 10.2174/1568009621666211103113339 Pashirzad M, Khorasanian R, Fard MM, Arjmand MH, Langari H, Khazaei M, et al. The therapeutic potential of MAPK/ERK inhibitors in the treatment of colorectal cancer. Curr Cancer Drug Targets. 2021 Dec 1;21(11):932-43. doi: 10.2174/1568009621666211103113339, PMID 34732116. 10.1021/acs.jmedchem.2c01244 Fu L, Chen S, He G, Chen Y, Liu B. Targeting extracellular signal-regulated protein kinase 1/2 (ERK1/2) in cancer: an update on pharmacological small-molecule inhibitors. J Med Chem. 2022 Oct 7;65(20):13561-73. doi: 10.1021/acs.jmedchem.2c01244, PMID 36205714. 10.3389/fmed.2023.1268479 Waseh S, Lee JB. Advances in melanoma: epidemiology, diagnosis, and prognosis. Front Med (Lausanne). 2023 Nov 22;10:1268479. doi: 10.3389/fmed.2023.1268479, PMID 38076247. 10.3390/cancers15123224 Fernandez MF, Choi J, Sosman J. New approaches to targeted therapy in melanoma. Cancers (Basel). 2023 Jun 17;15(12):3224. doi: 10.3390/ cancers15123224, PMID 37370834. 10.3390/cancers13225847 Khaddour K, Maahs L, Avila-Rodriguez AM, Maamar Y, Samaan S, Ansstas G. Melanoma targeted therapies beyond BRAF-mutant melanoma: potential druggable mutations and novel treatment approaches. Cancers (Basel). 2021 Nov 22;13(22):5847. doi: 10.3390/ cancers13225847, PMID 34831002. 10.3390/cancers15092607 Florent L, Saby C, Slimano F, Morjani H. BRAF V600-mutated metastatic melanoma and targeted therapy resistance: an update of the current knowledge. Cancers (Basel). 2023 May 4;15(9):2607. doi: 10.3390/cancers15092607, PMID 37174072. 10.1016/j.gendis.2022.04.004 Wagstaff W, Mwamba RN, Grullon K, Armstrong M, Zhao P, Hendren- Santiago B, et al. Melanoma: molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance. Genes Dis. 2022 Nov 1;9(6):1608-23. doi: 10.1016/j.gendis.2022.04.004, PMID 36157497. 10.3390/biom12121874 Li C, Kuai L, Cui R, Miao X. Melanogenesis and the targeted therapy of melanoma. Biomolecules. 2022 Dec 14;12(12):1874. doi: 10.3390/ biom12121874, PMID 36551302. 10.1080/15384047.2019.1640032 Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20(11):1366-79. doi: 10.1080/15384047.2019.1640032, PMID 31366280. 10.2174/1568026621666211111154342 Han X, Yu YL, Hu YS, Liu XH. 1,3,4-thiadiazole: A privileged scaffold for drug design and development. Curr Top Med Chem. 2021 Nov 1;21(28):2546-73. doi: 10.2174/1568026621666211111154342, PMID 34766891. 10.1007/s00253-022-11969-0 Atmaram UA, Roopan SM. Biological activity of oxadiazole and thiadiazole derivatives. Appl Microbiol Biotechnol. 2022 May;106(9- 10):3489-505. doi: 10.1007/s00253-022-11969-0, PMID 35562490. 10.1016/j.molstruc.2024.138438 Ahmad S, Alam MZ, Salma U, Mohasin M, Rahaman PF, Parveen H, et al. A review on recent progress in synthesis and biological activities of thiadiazole and its derivatives. J Mol Struct. 2024 Apr;1312:138438. doi: 10.1016/j.molstruc.2024.138438. 10.3390/molecules27092709 El-Masry RM, Kadry HH, Taher AT, Abou-Seri SM. Comparative study of the synthetic approaches and biological activities of the bioisosteres of 1,3,4-oxadiazoles and 1,3,4-thiadiazoles over the past decade. Molecules. 2022 Apr 22;27(9):2709. doi: 10.3390/molecules27092709, PMID 35566059. 10.1186/s43088-020-0037-5 Isyaku Y, Uzairu A, Uba S. QSAR and molecular docking studies of novel 2,5-distributed-1,3,4-thiadiazole derivatives containing 5-phenyl- 2-furan as fungicides against Phytophthora infestans. Beni Suef Univ J Basic Appl Sci. 2020;9(1):11. doi: 10.1186/s43088-020-0037-5. 10.1002/cem.3189 Gopinath P, Kathiravan MK. QSAR and docking studies on triazolebenzene sulfonamides with human carbonic anhydrase IX inhibitory activity. J Chemom. 2019;33(12):e3189. doi: 10.1002/ cem.3189. 10.1007/s13738-020-01932-z Sravanthi B, Kaviarasan L, Praveen TK, Sai Kiran PS, Pavankumar C, Gowramma B. Synthesis and pharmacological evaluation of 1,3,4-thiadiazole bearing pyrimidine derivatives as STAT3 inhibitor for treatment of breast cancer. J Iran Chem Soc. 2020;17(9):2359-70. doi: 10.1007/s13738-020-01932-z. 10.1080/10799893.2020.1800733 Lakshmanan K, Byran G. Identification of benzimidazole containing 4 H-chromen-4-one derivative as potential MAP kinase inhibitors by in silico approaches. J Recept Signal Transduct Res. 2021;41(2):153-8. doi: 10.1080/10799893.2020.1800733, PMID 32752909. 10.1016/B978-0-12-822312-3.00019-9 Kondapuram SK, Sarvagalla S, Coumar MS. Docking-based virtual screening using PyRx Tool: autophagy target Vps34 as a case study. In: Molecular docking for computer-aided drug design. Academic Press; 2021. p. 463-77. doi: 10.1016/B978-0-12-822312-3.00019-9. 10.2174/0115734072298465240403084903 Dilipkumar S, Karthik V, Gowramma B, Magesh M, Kaviarasan L. Synthesis, characterization, docking studies, and in vitro cytotoxic activity of some novel 2. Curr Bioact Compd. 2025;3 disubstituted naphthalene-1,4 dione derivatives:21:e160424228935. 10.31788/RJC.2024.1738857 Indhumathy P, Gandhimathi R. A review of recent developments in the biological activity of 1,3,4-thiadiazoles. Rasayan J Chem. 2024;17(3):809-19. doi: 10.31788/RJC.2024.1738857. 10.3390/cancers11091342 Fujimura T, Fujisawa Y, Kambayashi Y, Aiba S. Significance of BRAF kinase inhibitors for melanoma treatment: from bench to bedside. Cancers (Basel). 2019;11(9):1342. doi: 10.3390/cancers11091342, PMID 31514399. 10.1111/cas.13786 Chang F, Zhang Y, Mi J, Zhou Q, Bai F, Xu X, et al. ROCK inhibitor enhances the growth and migration of BRAF-mutant skin melanoma cells. Cancer Sci. 2018;109(11):3428-37. doi: 10.1111/cas.13786, PMID 30168234. 10.22159/ajpcr.2025v18i1.52907 Muthulakshmi R, Jamunarani R, Janani L, Sowmini K. A comparative study on efficacy and safety of streptokinase and Reteplase in patients with myocardial infarction in a tertiary care teaching hospital. Asian J Pharm Clin Res. 2025;18(1):39-41. doi: 10.22159/ ajpcr.2025v18i1.52907. 10.22159/ijap.2024v16i6.52154 Anusha M, Gubbiyappa KS. Bioanalytical method development and validation for the determination of asciminib anticancer drug in biological matrices by LC-ESI-MS/MS. Int J Appl Pharm. 2024;16(6):176-81. doi: 10.22159/ijap.2024v16i6.52154. 10.22159/ijap.2022v14i6.45818 Bhutia GT, Kumar De A, Bera T. Validation, stability studies, and simultaneous estimation of co-encapsulated curcumin, epigallocatechin gallate nanoformulation by RP- HPLC method. Int J Appl Pharm. 2022;14:186-95. doi: 10.22159/ijap.2022v14i6.45818.